Dr. Conor Farren

• Hartnett D, Murphy E, Kehoe E, Agyapong V, McLoughlin DM, Farren C, Supportive text messages for patients with alcohol use disorder and a comorbid depression: a protocol for a single-blind randomised controlled aftercare trial., BMJ open, 7, (5), 2017, p1 - 7Journal Article, 2017, DOI
• Agyapong VI, Farren C, McAuliffe E, Improving Ghana's mental healthcare through task-shifting- psychiatrists and health policy directors perceptions about government's commitment and the role of community mental health workers., Globalization and health, 12, (57), 2016Journal Article, 2016, DOI
• Agyapong VI, Osei A, Farren CK, McAuliffe E, Task shifting--Ghana's community mental health workers' experiences and perceptions of their roles and scope of practice., Global health action, 8, (1), 2015Journal Article, 2015, DOI
• Agyapong VI, Osei A, Farren CK, Mcauliffe E, Task shifting of mental health care services in Ghana: ease of referral, perception and concerns of stakeholders about quality of care., International journal for quality in health care : journal of the International Society for Quality in Health Care, 27, (5), 2015, p377 - 383Journal Article, 2015, DOI
• Agyapong VI, Osei A, Farren CK, McAuliffe E, Factors influencing the career choice and retention of community mental health workers in Ghana., Human resources for health, 13, (56), 2015Journal Article, 2015, DOI
• Thekiso TB, Murphy P, Milnes J, Lambe K, Curtin A, Farren CK, Acceptance and Commitment Therapy in the Treatment of Alcohol Use Disorder and Comorbid Affective Disorder: A Pilot Matched Control Trial., Behavior therapy, 46, (6), 2015, p717 - 728Journal Article, 2015, DOI
• Namkoong K, Farren CK, O'Connor PG, O'Malley SS, Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications., The Journal of clinical psychiatry, 60, (7), 1999, p449 - 453Journal Article, 1999, DOI
• Sinha R, Krishnan-Sarin S, Farren C, O'Malley S, Naturalistic follow-up of drinking behavior following participation in an alcohol administration study., Journal of substance abuse treatment, 1999Journal Article, 1999, DOI
• Farren CK, O'Malley S, Grebski G, Maniar S, Porter M, Kreek MJ, Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study., Alcoholism, clinical and experimental research, 23, (3), 1999, p502 - 508Journal Article, 1999, DOI
• Farren CK, Tipton KF, The urinary MHPG/creatinine ratio and its relationship to platelet monoamine oxidase activity in abstinent alcoholics., Addiction biology, 4, (1), 1999, p73 - 80Journal Article, 1999, DOI
• Oliveto AH, Farren C, Kosten TR, Effect of LAAM dose on opiate use in opioid-dependent patients. A pilot study., The American journal on addictions, 7, (4), 1998, p272 - 282Journal Article, 1998
• O'Connor PG, Farren CK, Rounsaville BJ, O'Malley SS, A preliminary investigation of the management of alcohol dependence with naltrexone by primary care providers., The American journal of medicine, 1997Journal Article, 1997, DOI
• Farren CK, Platelet monoamine oxidase (MAO) activity and alcoholism: is there a genuine association?, Addiction biology, 2, (2), 1997, p171 - 180Journal Article, 1997, DOI
• Farren CK, Dinan TG, Elevated tryptophan levels in post-withdrawal alcoholics., Acta psychiatrica Scandinavica, 94, (6), 1996, p465 - 470Journal Article, 1996, DOI
• Farren CK, Dinan TG, Platelet monoamine oxidase-B activity in alcoholics with lowered dopamine D2 receptor activity., Alcohol and alcoholism (Oxford, Oxfordshire), 31, 1996, p307 - 308Journal Article, 1996
• Breen E, Farren C, Connelly CE, McCarthy C, Collagenous colitis and coeliac disease. , GUT, 28, 1987, p364 - 365Journal Article, 1987
• Farren CK, Dinan TG, Involuntary movements in mentally handicapped women: relationship to age, neuroleptic exposure and level of handicap, Acta Psychiatrica Scandinavica, (90), 1994, p210 - 213Journal Article, 1994, DOI
• Naltrexone and Opiate Abuse in, editor(s)Kosten T, Stein S , New Treatments for Opiate Dependence: Which Treatments for Which Patients? , New York, Guilford Press, 1997, pp194 - 232, [Farren CK, O'Malley S, Rounsaville B]Book Chapter, 1997
• Depression and Substance Abuse in, editor(s)Tohen M , Comorbidity in Affective Disorder, USA, Marcel Decker, 1998, pp27 - 55, [Ziedonis DM, Farren CK, George T]Book Chapter, 1998
• Bipolar Affective and Alcohol Use Disorders: Comorbidity, consequences and Treatment in, editor(s)Dom G, Moggi F , Co-occurring Addictive and Psychiatric Disorders: A Practice-Based Handbook from a European Perspective, Heidelberg, Springer, 2015, pp119 - 135, [Preuss UW, Wong WMJ, Farren C]Book Chapter, 2015
• Alcohol and Alcoholism, Oxford, Oxford University Press, [eds.], 1999-2019Editorial Board, 1999
• Irish Journal of Medical Science, Dublin, Springer, [eds.], 2006-2016Editorial Board, 2006
• European Addiction Research, Basel, Karger, [eds.], 2018-2021Editorial Board, 2018
• Farren CK, Predicting Relapse after an Integrated Inpatient Treatment for Unipolar Depressed and Bipolar Patients, Alcoholism: Clinical and Experimental Research, Joint Meeting of Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Washington DC, USA, June 27 - July 2, 20, edited by RSA , 32, (6), Wiley Blackwell, 2008, pp323A-Conference Paper, 2008
• Krishnan-Sarin S, George T, O'Connor PG, Farren C, Torello R, O'Malley S, HPA axis responsivity: differential changes produced by alcohol and/or nicotine dependence, Alcoholism: Clinical and Experimental Research, Joint Meeting of Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Fort Lauderdale, FL, USA, June 21-June 25, edited by DW Crabb , 27, (5), Lappincott Williams and Wilkins, 2003, pp165A-Conference Paper, 2003
• Farren CK, Tang C, Kampov-Polevoi A, Gorelik L, Buchsbaum M, FMRI Scanning of Cue Induction and Craving in Alcoholism, Alcoholism: Clinical and Experimental Research, Joint Meeting of Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Fort Lauderdale, FL, USA, June 21-June 25, edited by DW Crabb , 27, (5), Lappincott Williams and Wilkins, 2003, pp168A-Conference Paper, 2003
• O'Malley S, McKee S, Krishnan-Sarin S, O'Connor P, Froehlich J, Farren CK, Namkoong K, Wu R, Rounsaville B, Can alternative behavioral strategies and settings enhance the outcome of naltrexone and for whom? , Alcoholism: Clinical and Experimental Research, Joint Meeting of Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, Fort Lauderdale, FL, USA, June 21-June 25, edited by DW Crabb , 27, (5), Lappincott Williams and Wilkins, 2003, pp191A-Conference Paper, 2003
• CNS Spectrums, 5, 2, (2000), 21 - 76p, Farren CK, [eds.], 1 IssueJournal, 2000
• Farren CK, Tang C, Kampov-Polevoi A, Gorelik L, Buchsbaum M, FMRI Scanning of Craving in Alcoholism, Alcoholism: Clinical and Experimental Research, Joint Meeting of Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, San Diego, CA, USA, June 28-July 3 2002, edited by TK Li , 26, (5), Lappincott Williams and Wilkins, 2002, pp26A-Conference Paper, 2002
• Kampov-Polevoi A, Garbutt J, Farren CK, Khalitov E, Sweet preference, TPG, and paternal history of alcoholism predict alcohol-related problems in young adults, Alcoholism: Clinical and Experimental Research, Joint Meeting of Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, San Francisco, CA, USA, June 28-July 3 2002, edited by TK Li , 26, (5), Lappincott Williams and Wilkins, 2002, pp53a-Conference Paper, 2002
• McKee S, sinha R, Farren C, O'Malley S, Modeling relapse as a function of time and amount consumed: the effect of naltrexone in alcohol dependent women, Alcoholism: Clinical and Experimental Research, Joint Meeting of Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, San Francisco, CA, USA, June 28-July 3 2002, edited by TK Li , 26, (5), Lappincott Williams and Wilkins, 2002, pp87a-Conference Paper, 2002
• O'Malley S, Sinha R, Farren C, Wu R, Grilo C, Hurley C, Meandzjia B, Naltrexone treatment in alcoholic women with and without eating disturbances, Alcoholism: Clinical and Experimental Research, Joint Meeting of Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism, San Francisco, CA, USA, June 28-July 3 2002, edited by TK Li , 26, (5), Lappincott Williams and Wilkins, 2002, pp129a-Conference Paper, 2002
• Farren CK, Milnes J, Lambe K, Ahern S, Computerised cognitive behavioral therapy for alcohol use disorder: a pilot randomised control trial, Irish Journal of Psychological Medicine, 32, (3), 2015, p237 - 246Journal Article, 2015, DOI
• Agyapong VIO, Sarvage M, Singh C, Farren CK, McLoughlin D, Use of codeine-containing medicines by patients admitted to an acute psychiatric hospital, European Psychiatry, 26, (1), 2011, p1-Journal Article, 2011, DOI
• Farren CK, Ziedonis D, Clare AW, Hameedi F, Dinai TG, D-fenfluramine induced prolactin responses in alcoholics and controls, Alcoholism: Clinical and Experimental Research, 19, 1995, p1578 - 1582Journal Article, 1995, DOI
• Farren CK, Clare AW, Hameedi FA, Ziedonis D, Dinan TG, Evidence for reduced dopamine D2 receptor sensitivity in postwithdrawal alcoholics, Alcoholism: Clinical and Experimental Research, 19, 1995, p1520 - 1524Journal Article, 1995, DOI
• Farren CK, Clare AW, Dinan TG, Basal serum cortisol and dexamethasone induced growth hormone release in the alcohol dependence syndrome, Human Psychopharmacology: Clinical and Experimental, 10, 1995, p207 - 213Journal Article, 1995, DOI
• Farren CK, Dinan TG, High serum tryptophan associated with evidence for diminished central serotonin function in abstinent alcoholics, Human Psychopharmacology: Clinical and Experimental, 11, 1996, p511 - 516Journal Article, 1996, DOI
• Gannon M, Meagher D, Johnson J, Mirza H, Farren C, A survey of the new long stay patients in an Irish Health Board area, Psychiatry Services, 46, 1995, p394 - 398Journal Article, 1995, DOI
• Farren CK, Serotonin and alcoholism: clinical and experimental research, Journal of Serotonin Research, 1, 1996, p6 - 28Journal Article, 1996
• Cooney JM, Farren CK, Clare AW, The incidence of personality disorder among first ever admissions to an Irish public and private hospital, Irish Journal of Psychological Medicine, 13, 1996, p6 - 8Journal Article, 1996, DOI
• Farren CK, The use of naltrexone, an opiate antagonist, in the treatment of opiate addiction, Irish Journal of Psychological Medicine, 14, 1997, p31 - 34Journal Article, 1997, DOI
• Thekiso TB, Farren CK, A study of 'Over the Counter' opiate abuse treatment, Irish Journal of Psychological Medicine, 27, (4), 2010, p189 - 191Journal Article, 2010, DOI
• O'Reilly H, Hagerty A, O'Donnell S, Farrell A, Hartnett D, Murphy E, Kehoe E, Agyapong V, McLoughlin DM, Farren C., Alcohol Use Disorder and Comorbid Depression: A Randomized Controlled Trial Investigating the Effectiveness of Supportive Text Messages in Aiding Recovery., Alcohol and alcoholism (Oxford, Oxfordshire), 54, (5), 2019, p551-558Journal Article, 2019, DOI
• Farren CK, Farrell A, Hagerty A, McHugh C, A Six-month Randomised Trial of a Smartphone Application, UControlDrink, in Aiding Recovery in Alcohol Use Disorder, European Addiction Research, 2021Journal Article, 2021
• Farren, C. K., Clare, A. W., Tipton, K. F., and Dinan, T. G., Platelet MAO activity in subtypes of alcoholics and controls in a homogenous, J. Psychiatr. Res. , 32, 1998, p49 - 54Journal Article, 1998, DOI
• Farren, C. K. and Tipton, K. F., Trait markers for alcoholism: clinical utility. , Alc. Alcoholism , 34, 1999, p649 - 665Journal Article, 1999, DOI
• Farren C, McLoughlin D, Clare A. , Procedures for involuntary admission to public and private psychiatric facilities. , Irish Journal of Psychological Medicine, 9, (2), 1992, p96-100Journal Article, 1992
• Agyapong V.I.O., Farren C.K. and McLoughlin D, Mobile phone text message interventions in psychiatry- what are the possibilities?, Current Psychiatry Reviews, 7, (1), 2011, p1 - 7Journal Article, 2011, DOI
• Agyapong V.I.O., Singh K., Savage M., Thekiso B.T., Finn M, Farren C.K. McLoughlin D.M., Use of codeine-containing medicines by Irish psychiatric in-patients before and after regulatory limitations on their supply. , Irish Journal of Psychological Medicine, 30, (01), 2013, p7 - 12Journal Article, 2013, DOI , TARA - Full Text
• Agyapong, V.I.O., McLoughlin, D.M., Farren, C.K., Six-months outcomes of a randomised trial of supportive text messaging for depression and comorbid alcohol use disorder, Journal of Affective Disorders, 151, (1), 2013, p100-104Journal Article, 2013, DOI
• Farren,Conor Kevin C.K., Snee,Laura L., Daly,Pamela P., McElroy,Sharon S., Prognostic factors of 2-year outcomes of patients with comorbid bipolar disorder or depression with alcohol dependence: Importance of early abstinence, Alcohol and Alcoholism, 48, (1), 2013, p93-98Journal Article, 2013, DOI , TARA - Full Text
• Farren,Conor Kevin C.K., Murphy,Philip G. P.G., McElroy,Sharon S., A 5-Year Follow-Up of Depressed and Bipolar Patients with Alcohol Use Disorder in an Irish Population, Alcoholism: Clinical and Experimental Research, 38, (4), 2014, p1049-1058Journal Article, 2014, DOI
• Farren,Conor Kevin C.K., McElroy,Sharon S., Predictive factors for relapse after an integrated inpatient treatment programme for unipolar depressed and bipolar alcoholics, Alcohol and Alcoholism, 45, (6), 2010, p527-533Journal Article, 2010, DOI
• Farren,Conor Kevin C.K., Snee,Laura L., McElroy,Sharon S., Gender differences in outcome at 2-year follow-up of treated bipolar and depressed alcoholics, Journal of Studies on Alcohol and Drugs, 72, (5), 2011, p872-880Journal Article, 2011, DOI
• Farren,Conor Kevin C.K., Mc Elroy,Sharon L. S.L., Treatment response of bipolar and unipolar alcoholics to an inpatient dual diagnosis program, Journal of Affective Disorders, 106, (3), 2008, p265-272Journal Article, 2008, DOI
• Farren,Conor Kevin C.K., Hill,Kevin P. K.P., Weiss,Roger D. R.D., Bipolar disorder and alcohol use disorder: A review, Current Psychiatry Reports, 14, (6), 2012, p659-666Journal Article, 2012, DOI
• Agyapong,Vincent Israel Opoku V.I.O., Ahern,Sinead S., McLoughlin,Declan Marcellino D.M., Farren,Conor Kevin C.K., Supportive text messaging for depression and comorbid alcohol use disorder: Single-blind randomised trial, Journal of Affective Disorders, 141, (2-3), 2012, p168-176Journal Article, 2012, DOI
• Agyapong,Vincent Israel Opoku V.I.O., Milnes,Jennie J., McLoughlin,Declan Marcellino D.M., Farren,Conor Kevin C.K., Perception of patients with alcohol use disorder and comorbid depression about the usefulness of supportive text messages, Technology and Health Care, 21, (1), 2013, p31-39Journal Article, 2013, DOI
• Farren,Conor Kevin C.K., Dinan,Timothy G. T.G., Alcoholism and typology: Findings in an Irish private hospital population, Journal of Studies on Alcohol, 57, (3), 1996, p249-252Journal Article, 1996, DOI
• Farren,Conor Kevin C.K., Scimeca,Michael M. M.M., Wu,Ran R., Malley,Stephanie O. S.O., A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence, Drug and Alcohol Dependence, 99, (1-3), 2009, p317-321Journal Article, 2009, DOI
• O'Malley,Stephanie Samples S.S., Sinha,Rajita R., Grilo,Carlos M. C.M., Capone,Christy C., Farren,Conor Kevin C.K., McKee,Sherry A. S.A., Rounsaville,Bruce James B.J., Wu,Ran R., Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: A randomized controlled trial, Alcoholism: Clinical and Experimental Research, 31, (4), 2007, p625-634Journal Article, 2007, DOI
• Farren,Conor Kevin C.K., O'Malley,Stephanie Samples S.S., A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence, American Journal on Addictions, 11, (3), 2002, p228-234Journal Article, 2002, DOI
• O'Malley,Stephanie Samples S.S., Krishnan-Sarin,Suchitra S., Farren,Conor Kevin C.K., Sinha,Rajita R., Kreek,Mary Jeanne M.J., Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis, Psychopharmacology, 160, (1), 2002, p19-29Journal Article, 2002, DOI
• Froehlich, J.C., O'Malley,S.S., Hyytia P., Davidson,D.W., Farren,C.K., Preclinical and clinical studies on naltrexone: What have they taught each other?, Alcoholism: Clinical and Experimental Research, 27, (3), 2003, p533-539Journal Article, 2003, DOI
• Farren,Conor Kevin C.K., O'Malley,Stephanie Samples S.S., Occurrence and management of depression in the context of naltrexone treatment of alcoholism, American Journal of Psychiatry, 156, (8), 1999, p1258-1262Journal Article, 1999
• Farren,Conor Kevin C.K., O'Malley,Stephanie Samples S.S., Sequential use of naltrexone in the treatment of relapsing alcoholism [6], American Journal of Psychiatry, 154, (5), 1997, p714Journal Article, 1997
• Farren,Conor Kevin C.K., Rezvani,Amir Hosein A.H., Overstreet,David David D.D., O'Malley,Stephanie Samples S.S., Combination pharmacotherapy in alcoholism: A novel treatment approach, CNS Spectrums, 5, (2), 2000, p70-76Journal Article, 2000, DOI
• Farren,Conor Kevin C.K., Alcoholism: A disorder with a past, CNS Spectrums, 5, (2), 2000, p21Journal Article, 2000, DOI
• Roth,Augusta S. A.S., Hogan,Izola I., Farren,Conor Kevin C.K., Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals, Journal of Substance Abuse Treatment, 14, (1), 1997, p19-22Journal Article, 1997, DOI
• Farren,Conor Kevin C.K., Hameedi,Faiq A. F.A., Rosen,Marc A. M.A., Woods,Scott W. S.W., Jatlow,Peter I. P.I., Kosten,Thomas R. T.R., Significant interaction between clozapine and cocaine in cocaine addicts, Drug and Alcohol Dependence, 59, (2), 2000, p153-163Journal Article, 2000, DOI
• O'Malley,Stephanie Samples S.S., Rounsaville,Bruce James B.J., Farren,Conor Kevin C.K., Namkoong,Kee K., Wu,Ran R., Robinson,Jane E. J.E., O'Connor,Patrick G. P.G., Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: A nested sequence of 3 randomized trials, Archives of Internal Medicine, 163, (14), 2003, p1695-1704Journal Article, 2003, DOI
• O'Malley,Stephanie Samples S.S., Krishnan-Sarin,Suchitra S., Farren,Conor Kevin C.K., O'Connor,Patrick G. P.G., Naltrexone-induced nausea in patients treated for alcohol dependence: Clinical predictors and evidence for opioid-mediated effects, Journal of Clinical Psychopharmacology, 20, (1), 2000, p69-76Journal Article, 2000, DOI

• Conor Farren, Overcoming Alcohol Misuse: A 28 Day Guide, 1st, Dublin, Orpen Press, 2011, 1 - 320ppBook
• Conor Farren, The U Turn: A Guide to Happiness, 1st, Dublin , Orpen Press, 2013, 1 - 304ppBook
• Farren CK, Treatment effects of an inpatient dual diagnosis program upon depressed and bipolar alcoholics, College of Psychiatrists of Ireland, Dublin, March, 2006, College of Psychiatrists of IrelandInvited Talk
• Farren CK, Bipolar Disorder and Alcohol Dependence: A Complex Interaction, International Congress on Bipolar Disorders, Athens, Feb 19, 2011, World Federation of Societies of Biological PsychiatryInvited Talk
• Farren CK, NICE Guidelines for the treatment of alcohol use disorder, Albatros Congress, French Society of Addictionology, Paris, June, 2013, Albatros CongressInvited Talk
• Farren CK, Treatment of substance use disorder and bipolar disorder: Longitudinal follow-up data and treatment interventions, Annual Congress, Leuven, Belgium, Dec , 2013, Belgian College of Neuropsychopharmacology and Biological PsychiatryInvited Talk
• Farren CK, Treatment of Dual Diagnosis, Annual Congress, Helsinki, Finland, June, 2014, Finnish Society for Addiction MedicineInvited Talk
• Farren CK, Updates on Alcohol Pharmacotherapy, Annual Congress, Kildare, Ireland, November, 2014, College of Psychiatrists of IrelandInvited Talk
• Farren CK, Future horizons in patient care using social media and new technology, Progress in Mine: Focus on Alcohol Use Disorder, Paris, November 16, 2014, ElsevierInvited Talk
• Farren CK, The use of technology in the treatment of AUD, World Congress on Alcoholism and Alcohol Abuse, Berlin, September, 2016, International Society for Biomedical Research on AlcoholismInvited Talk
• Farren CK, Alcohol and Affective Disorder (Plenary), Annual Congress, Lisbon Portugal, November, 2016, Portugese Foundation for the Study, Prevention and Treatment of DependenciesInvited Talk
• Farren CK, Technology and Addiction: A New Frontier, The Next Generation of Progress, Heidelberg, Germany, February 24, 2017, Heidelberg University,Invited Talk
• Farren CK, Addictions in an Increasingly Connected Age, Albatros Congress, French Society of Addictionology, Paris, June 5, 2017, French Society of AddictionologyInvited Talk
• Farren CK, The use of Technology in addiction, Florida and Opiates: The Treatment Imperative, Orlando Florida, October 22, 2018, Gladwell Institute and Health XLInvited Talk
• Farren CK, Behavioral Addiction: A New Type of Addictive Disorder, Academic Day: Cyberspace A New Frontier for Medicine and Law, Dublin, February 16, 2019, The Medico-Legal Society of IrelandInvited Talk
• Farren CK, Managing Alcohol in General Practice, Summer School, Kilkenny, June 20, 2013, Irish College of General PractitionersInvited Talk
• Farren CK, Supportive text messages for patients with alcohol use disorder and a co-morbid depression. Six-month randomised controlled trial with aftercare, Alcoholism: Clinical and Experimental Research, International Society for Biomedical Research on Alcoholism, Kyoto, Japan, September 2018, 2018Oral Presentation
• Farren CK, An Overview of European Addiction Clinical Guidelines, Setting Standards in the Addiction Field: A View from Europe, Lisbon Portugal, October 24, 2017, European Conference on Addictive Behavior and DependenceInvited Talk
• Farren CK, U Control Drink: A New Treatment for Alcohol Abuse, Annual Congress, Barcelona, Spain, May, 2017, Health 2.0Invited Talk
• Farren CK, Trauma: Alcohol Misuse and Mental Health, Traumatic Stress, Alcohol and Drug Conference, Lisburn, NI, December 14, 2011, Office of the First Minister and Deputy First MinisterInvited Talk
• Farren CK, Who are the patients with depression more likely to abuse alcohol? , International Congress on Dual Disorders, Barcelona, Spain, April 17, 2015, Congress on Dual DisordersInvited Talk
• Thekiso T, Farren CK, Acceptance and Committment Therapy (ACT): a pilot mindfulness-based psychotherapeutic clinical trial in a dual diagnosis population, European Society for Biomedical Research on Alcoholism, Warsaw, Poland, September 10, 2013, ESBRAInvited Talk
• Ahern S, Agyapong V, Farren CK, Supportive text messaging for depression and comorbid alcohol use disorder: single blind randomised trial, European Society for Biomedical Research on Alcoholism, Warsaw, Poland, September 10, 2013, ESBRAInvited Talk
• Farren CK, Computerised Cognitive Behavioral Therapy for Alcohol Use Disorder: A Pilot Placebo-Controlled Trial; Symposium Chair, European Society for Biomedical Research on Alcoholism, Warsaw, Poland, September 10, 2013, ESBRAInvited Talk
• Farren CK, 2-year Tx Outcome: Bipolar Vs. Depressed Alcoholics, Annual Congress, International Society for Affective Disroders, London, UK, April 18, 2012, ISADInvited Talk
• Farren CK, McElroy S, A 2-year follow-up of treated and untreated bipolar and depressed alcoholics, World Congress of Psychiatry, Buenos Aires, Argentina, September 18, 2011, World Psychiatric AssociationInvited Talk
• Farren CK, Technology and the Treatment of Alcohol Misuse, Founders Day, Dublin, November 30, 2017, St Patrick's University HospitalInvited Talk
• Farren CK, The Relationship between Alcohol and Mental Health, Facing the Fear: Alcohol and Mental Health in Ireland, Dublin, November 20, 2014, Alcohol Action IrelandInvited Talk
• Farren CK, A 2-year follow-up on inpatient treatment for depressed and bipolar alcoholics, International Society for Biomedical Research on Alcoholism, Paris, France, September, 2010, ISBRAInvited Talk
• Farren CK, Prediction of relapse after an inpatient treatment of an affective and alcohol dependence program, European Society for Biomedical Research on Alcoholism, Helsinki, Finland, June, 2009, ESBRAInvited Talk
• Farren CK, Depression and Dual diagnosis, Psychiatry Update and Future Direction, Dublin, September, 2012, Pfizer LtdInvited Talk
• Farren C, MacLoughlin D, Clare A, Procedures for Involuntary Admissions in Ireland, Presented at the Royal College of Psychiatrists Annual Meeting, Dublin, 1992Poster
• Farren CK, Dinan TG, Dyskinesia in the mentally handicapped, Presented at the Royal Academy of Medicine in Ireland, Psychiatry Section, Ireland, 1993Poster
• Farren CK, Clare AW, Hameedi FA, Ziedonis DM Dinan TG, Growth hormone responses to bromocriptine in alcoholics and controls, Presented at the American Psychiatric Association Annual Meeting, Philadelpia, USA, 1994Poster
• Farren CK, Clare AW, Hameedi FA, Ziedonis DM, Dinan TG, Prolactin response to d-fenfluramine in alcoholics and controls, Presented at the American Psychiatric Association Annual Meeting, Philadelpia, USA, 1994Poster
• Farren CK, Clare AW, Dinan TG, Dexamethasone-induced growth hormone release in the alcohol dependence syndrome. , Presented at the American College of Neuropsychopharmacology, San Juan, Peurto Rico, 1994Poster
• Hameedi FA, Rosen MI, Price LH, Farren CK, Woods SW, Kosten TR, Serotonergic function during acute and chronic cocaine abstinence, Presented at the College of Problems on Drug Dependence, 1994Poster
• Ziedonis DM, Farren CK, Kosten TR, Depression in cocaine abusing opioid addicts treated with buprenorphine versus methadone, Presented at the College of Problems on Drug Dependence, 1994Poster
• Gill TS, Ziedonis DM, Farren CK, Wallace EA, Schottenfeld RS, A survey of sleep problems in a substance abusing population, Presented at the College of Problems on Drug Dependence, USA, 1994Poster
• Farren CK, Clare AW, Tipton K, Dinan TG: , Platelet MAO activity in alcoholics, Presented at the Research Society on Alcoholism, 1995Poster
• O'Connor P, O'Malley S, Farren C, Treatment of alcohol dependence with naltrexone by primary care providers, Presented at the College of Problems on Drug Dependence, 1995Poster
• Farren CK, Dinan TG, Alcoholism and typology: relationship to age of onset, family history and serum cortisol, Presented at the American Psychiatric Association Annual Meeting, Miami, USA, 1995Poster
• O'Malley S, Sinha R, Farren CK, Krishnan-Sarin S, Kreek MJ, Naltrexone modification of alcohol effects in alcohol dependent subjects, Presented at the Research Society on Alcoholism, Texas, USA, 1995Poster
• Lazrove S, Triffleman E, Farren CK, Rounsaville B, EMDR in the treatment of PTSD, Presented at the international Society for Traumatic Stress Studies, Illinois, USA, 1995Poster
• Farren CK, Dinan TG, Elevated tryptophan levels in post withdrawal alcoholics, Presented at the American College of Neuropsychopharmacology, San Juan, Peurto Rico, 1995Poster
• Oliveto A, Farren CK, Kosten T, LAAM in the treatment of cocaine abusing opiate addicts, Presented at the American College of Neuropsychopharmacology, San Juan, Peurto Rico, 1995Poster
• Presented at the American College of Neuropsychopharmacology, EKG findings in cocaine addicts, Presented at the American College of Neuropsychopharmacology, San Juan, Peurto Rico, 1995Poster
• Roth A, Farren CK, Naltrexone in the treatment of opiate abusing health professionals, Presented at the Association for Medical Education and Research in substance Abuse, Rhode Island, USA, 1995Poster
• Hameedi FA, Farren CK, Rosen MI, Pearsall HR, Kosten TK, Self-administration of cocaine in humans, a pilot study, Presented at the College of Problems on Drug Dependence, Philadelphia, USA, 1996Poster
• Farren CK, Dinan TG, High serum tryptophan associated with evidence for diminished central serotonin function in abstinent alcoholics, Presented at the Research Society on Alcoholism, Texas, USA, 1996Poster
• O'Malley SS, Krishnan-Sarin S, Farren CK, O'Connor PG, Golubchikov V, Rounsaville BJ, Predictors of naltrexone induced nausea in alcohol dependent subjects, Presented at the Research Society on Alcoholism, Texas, USA, 1996Poster
• Krishnan-Sarin S, Rosen MI, Farren CK, Bernardy NC, O'Malley S, Opioid involvement in nicotine and alcohol dependence. , Presented at the Research Society on Alcoholism, Texas, USA, 1996Poster
• O'Malley S, Krishnan-Sarin S, Farren CK, Sinha R, Nicotine pretreatment attenuates naltrexone-induced side effects in alcoholic smokers. , Presented at the Research Society on Alcoholism, Texas, USA, 1996Poster
• Farren CK, O'Malley S, Grebski G, Marniar S, Potter ML, Gunduz M, Kreek MJ, Variable dose naltrexone induced HPA activation in abstinent alcoholics, Presented at the American College of Neuropsychopharmacology, Tennesse,USA, 1996Poster
• Presented at the American College of Neuropsychopharmacology, Variable dose naltrexone induced HPA activation in abstinent alcoholics. , Tennesse,USA, 1997Poster
• Namkoong K, Farren CK, O'Connor P, O'Malley S, Compliance of naltrexone in the treatment of alcohol dependence, Presented at the Research Society on Alcoholism, Texas, USA, 1997Poster
• O'Malley S, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ, Naltrexone modification of alcohol self-administration in alcohol dependent subjects, Presented at the Research Society on Alcoholism, Texas, USA, 1997Poster
• Farren CK, Catapano D, O'Malley S, Sertraline with naltrexone versus naltrexone alone in the treatment of alcohol dependence, Presented at the Research Society on Alcoholism, Texas, USA, 1997Poster
• O'Malley S, O'Connor P, Farren CK, Rounsaville B, Naltrexone treatment of alcohol dependence with primary care versus relapse prevention psychotherapy, Presented at the American College of Neuropsychopharmacology, Tennesse,USA, 1997Poster
• Farren CK, O'Malley S, Kreek MJ, A comparison between naltrexone induced HPA stimulation in healthy controls in abstinent alcoholics, Presented at the Research Society on Alcoholism, Texas, USA, 1998Poster
• Krishnan-Sarin S, Matthews E, Steinman D, Farren C, O'Malley S, Naloxone challenge in alcoholic smokers, Presented at the Research Society on Alcoholism, Texas, USA, 1998Poster
• Farren CK, O'Malley S, Kreek MJ, Central opioid tone in alcoholism: naltrexone induced hypothalamic-pituitary-adrenal axis stimulation, Presented at the American College of Neuropsychopharmacology, Tennesse,USA, 1998Poster
• Farren CK, O'Malley SS, Krishnan-Sarin S, Tilton R, Kreek MJ: , Differing response to high naltrexone doses: treatment implications for alcoholism. , Presented at the Research Society on Alcoholism, , Texas, USA, 1999Poster
• Krishnan-Sarin S, Sinha R, Farren C, Wu R, Kreek MJ, O'Malley SS: , Evidence of lower prolactin levels in alcohol smokers versus alcoholic nonsmokers. , Presented at the Research Society on Alcoholism, Texas, USA, 1999Poster
• Sinha R, Hurley C, Farren C, O'Malley SS, Co-morbid psychopathology, eating pathology and dependence severity in treatment-seeking alcoholic women, Presented at the Research Society on Alcoholism, Texas, USA, 1999Poster
• O'Malley S, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ, Naltrexone augments neuroendocrine responses to ethanol in alcohol dependent subjects., Presented at the Research Society on Alcoholism, Texas, USA, 1999Poster
• Farren CK, O'Malley S, Tilton R, Kreek MJ, Opioid abnormalities in alcoholism: naltrexone induced responses. , Presented at the Research Society on Alcoholism, Texas, USA, 2000Poster
• Krishnan-Sarin S, George T, O'Connor PG, Farren C, O'Malley S, Alcohol and nicotine dependence: evidence for differential HPA axis dysfunction, Presented at the American College of Neuropsychopharmacology, Tennesse,USA, 2000Poster
• Farren CK, Buchsbaum MS, Chiu J, Shaw RB, Differences between newly abstinent alcoholics and healthy controls using FDG-PET scanning, Presented at the American College of Neuropsychopharmacology, Tennesse,USA, 2000Poster
• Farren CK, O'Malley S, Tilton R, Kreek MJ: , Opioid abnormalities in alcoholism: naltrexone induced responses, Presented at the Society of Biological Psychiatry Annual Meeting, Chicago, IL, USA, 2000Poster
• Farren CK, Buchsbaum M, Hazlett E, Banks A, FDG-PET scanning in newly abstinent alcoholics: Fronto-striatal abnormalities. , Presented at the Research Society on Alcoholism, Texas, USA, 2001Poster
• Kampov-Polevoy A, Garbutt JC, Farren CK, Khalitov E, Sweet preference, TPQ, and paternal history of alcoholism predict alcohol-related problems in young adults, Presented at the Research Society on Alcoholism, Texas, USA, 2002Poster
• McKee S, Sinha R, Farren CK, O'Malley S, Modeling relapse as a function of time and amount consumed: the effect of naltrexone in alcohol dependent women. , Presented at the Research Society on Alcoholism, Texas, USA, 2002Poster
• O'Malley S, Sinha R, Farren CK, Wu R, Grilo C, Hurley C, Meandzjia , Naltrexone treatment in alcoholic women with and without eating disturbances, Presented at the Research Society on Alcoholism, Texas, USA, 2002Poster
• Farren CK, Tang C, Kampov-Polevoi A, Gorelik L, Buchsbaum MS, fMRI scanning of craving in alcoholism. , Presented at the Research Society on Alcoholism, Texas, USA, 2002Poster
• O'Malley S, McKee S, Krishnan-Sarin S, O'Connor P, Froehlich J, Farren CK, Namkoong K, Wu R, Rounsaville B: , Can alternative behavioral strategies and settings enhance the outcome of naltrexone and for whom? , Presented at the Research Society on Alcoholism, Texas, USA, 2003Poster
• Krishnan-Sarin S, George TP, O'Connor PG, Farren C, Torello R, O'Malley S: , HPA axis responsivity: differential changes produced by alcohol and/or nicotine dependence, Presented at the Research Society on Alcoholism, Texas, USA, 2003Poster
• Farren CK, Treatment Update for Traffic Medicine, Royal College of Physicians Of Ireland, Traffic Medicine Institute, Dublin, Remote, Oct 9, 2020, 2020, Institute of Traffic MedicineInvited Talk
• Farren CK, Alcohol in the Pandemic, Irish College of General Practitioners, Dublin, Remote, April 24, 2021, 2021, Irish College of General PractitionersInvited Talk
• Farren CK, Alcohol Use Disorder and Comorbid Depression: A Randomized Controlled Trial Investigating the Effectiveness of Support Text Messages in Aiding Recovery, ESBRA Conf Proceedings, European Society for Biomedical Research on Alcoholism, Lille France, Sept 2019, 2019Poster

• Title

  Yale Medication Development Research Center
  Summary

  Co-investigator, significant protocol development and grant writing component, successfully developed and ran human laboratory based medication administration paradigm, analysed data and wrote manuscript (1st author), presented at CPDD 1996, published 1999. Pioneered use of atypical antipsychotic medication in addictive disorders.
  Funding Agency

  National Institute on Drug Abuse
  Date From

  9-1-94
  Date To

  8-31-99
• Title

  Text Messaging Support for Depression and Alcohol Use Disorder
  Summary

  Project Abstract Co-morbidity of alcohol use disorders and mood disorders presents great challenge to health systems and exact a tremendous toll world-wide. Individuals with the dual disorder have more severe symptoms, greater disability and poor quality of life than individuals with only alcohol use disorder, and pose a greater economic burden to society due to their higher use of treatment services. We seek to develop a new, enhanced, efficient, innovative and cost effective treatment strategies aimed at reducing the burden that the disorders impose on the suffers and their families as well as the community and health systems. In a pilot trial of supportive text messages for patients with alcohol use disorders and comorbid depression, we established that patients who received twice daily supportive text messages for three months had significantly less depressive symptoms than those who did not receive such messages. There was also a trend to finding that patients who received the supportive text messages were more likely to have higher cumulative abstinence duration than those who did not receive any supportive text messages. This research seeks to extend the knowledge gained from the pilot trial. We will conduct a randomised trial on a larger sample size of patients with an alcohol use disorders and a comorbid mood disorder (including bipolar depression) for an extended duration (Six months supportive text messages and 1 year follow-up instead of three months text messages with six months follow-up in the pilot trial). We hypothesis that patients receiving supportive text messages would report significantly greater cumulative abstinence duration as well as significantly less relapses, hospitalizations and mood symptoms than those not receiving such messages. The technology would also be acceptable to patients as well as cost effective.
  Funding Agency

  Health Research Board
  Date From

  01-01-2015
  Date To

  30-12-2017
• Title

  A Clinical Trial of a Smartphone App for the Treatment of Alcohol Use Disorder
  Summary

  There is increasing evidence to suggest that mobile health (mHealth) applications can be a therapeutically and cost effective means of treating Alcohol Use Disorders (AUD) and problem drinking (Riper et al., 2011; Quanbeck, et al., 2014). Agyapong et al. (2012) found, for example, in a single-blind randomised controlled trial of twice daily text messages targeting depression and comorbid AUD, that those who received text messages had significantly lower depressive symptoms at three months follow-up than those who received treatment as usual, with a trend toward fewer drinking days in the text message group also. Similarly, Gustafson et al. (2014) found, in a multi-site non-blind randomised controlled trial involving alcohol dependant adults, that an integrated monitoring, information communication, and therapeutic support mHealth application led to significantly fewer risky drinking days for those in the mHealth group compared to the control group. mHealth applications may be particularly suited to treating AUD and problem drinking as they allow for real-time monitoring, therapeutic support, and positive reinforcement of recovery activity when and where this is needed, and in a convenient location and format. mHeatlh applications thus have the potential to allow for significantly greater utilisation of therapeutic resources than is traditional, and these resources will be considerably cheaper than the currently available therapeutic interventions as they are delivered through technology. Aims To conduct a non-blind controlled trial of U Control Drink to assess its effectiveness with an alcohol abusing and /or dependant CRI population. Techniques and Methodology (including any assessment measures) Participants Participants will be approximately 100 alcohol abusing and/or dependant service users referred to CRI. Assessment Instruments The Alcohol Use Disorders Identification Test (AUDIT) will be used to assess severity of alcohol abuse and dependence problems. A number of other clinically relevant indices such as number of logged drinks will be automatically collected by the U Control Drink application. Participants will additionally complete a brief usability questionnaire (BUQ) in relation to their experience of using the application. Method Following routine baseline assessment participants will be assigned to receive either treatment as usual (TAU) or TAU + U Control Drink (TAU+UCD). Group assignment will be based on alternate group allocation whereby participants will be alternately assigned to each group on a 1:1 basis. An appropriate healthcare professional will administer the AUDIT during routine baseline assessment (Time 1), and the AUDIT+BUQ at 3-month follow-up (Time 2). Participants allocated to the TAU+UCD group who score below 8 on the AUDIT will be offered access to UCD in addition to routine advice and eHealth treatment. Those scoring between 8 and 20 will be offered UCD in parallel with motivational enhancement therapy, and pharmacotherapy if appropriate. For participants scoring above 20, and who require inpatient detoxification, TAU+UCD will be offered in parallel to routine treatment post-discharge.
  Funding Agency

  Health Research Board
  Date From

  01-06-2019
  Date To

  31-05-2023
• Title

  Initial and Maintenance Naltrexone for Alcohol Dependence,
  Summary

  Co-investigator, medical director of the protocol, Running a clinical trial of maintenance naltrexone for alcohol dependence, running 197 patients for a total of 9 months each over 6 years, with significant protocol development and manuscript writing input.
  Funding Agency

  National Institute on Alcoholism and Alcohol Abuse.
  Date From

  9-30-92
  Date To

  8-31-98
• Title

  Double-Blind Parallel Comparison of Sertraline and Placebo in Patients with Depression and a DSM-IV Diagnosis of Alcohol Dependence,
  Summary

  Co-investigator, medical director of large multi site clinical trial, significant design and protocol development input, results presented at RSA, 2000
  Funding Agency

  Pfizer Ltd. (IND# 18000,004)
  Date From

  3-1-97
  Date To

  9-1-98
• Title

  Naltrexone: Consummatory Behaviors in Alcoholic Women,
  Summary

  Co-investigator, medical director of clinical trial of pharmacotherapy and psychotherapy for 97 dually diagnosed women over 5 years, significant design and protocol development input, results presented at RSA 1999, 2002. Manuscript published.
  Funding Agency

  National Institute on Alcoholism and Alcohol Abuse.
  Date From

  2-1-95
  Date To

  1-31-00
• Title

  Nicotine and Alcohol Dependence: Opioid Involvement,
  Summary

  Co-investigator, medical director of human laboratory paradigm of dually addicted volunteers, significant design and protocol development input, with results analysis, presented at RSA 1999, 2000, and ACNP 2000.
  Funding Agency

  National Institute on Alcoholism and Alcohol Abuse.
  Date From

  9-29-96
  Date To

  9-30-99
• Title

  Development of The Your Turn, an e-health platform for the management and treatment of alcohol misuse in the EU: Effective outreach in five different cultural settings in the EU.
  Summary

  E-therapy is a developing area of medicine, and it is being increasing used to deliver effective results in a variety of health disorders, embracing a variety of technologies to improve accessibility and effective delivery of treatment to more people. Mental health issues, including addictive disorders, lend themselves to being treated via e-therapy probably more than any other of medicine. The treatment trial could have a TAU group, a TAU plus theyouturn group, delivered online. Economic benefit analysis could thus have a costing of each of the three groups, according to different costs of the interventions. There will also be a pre-clinical group, recruited online, or by advertisement, consisting of a study control group, a technology intervention group, and a technology intervention plus weekly online therapist group. The numbers are outlined in the attached study design. For each setting, and each language, there would be a need to adjust support mechanisms for that particular setting. For example text messaging support would have to be sent in the appropriate language, and with culturally sensitive messages. Chat rooms and personal feedback would have to be developed in a language appropriate and culturally appropriate manner. Each support technology would have to be tested in the appropriate setting, as different cultures are likely to gain benefit from different supports according to locally effective recovery principles. For example, text messaging support may prove effective in Germany, and chat - room and peer support may prove more effective in Spain. Thus the project divides itself into three components, in each of the five regions. Firstly each regional director would have to set up focus groups, and stakeholder feedback regarding the most appropriate balance of technologies for their own setting. This would be in the form of small group testing of service users, and utilisation of the feedback to make up a premium package for that country. Technology, initially developed for Ireland, would need to be translated into four other languages, and each component tested in the appropriate population. Upon completion of this alpha testing phase, a technological package for each region will be decided upon by each regional director, in conjunction with the project coordinator. Upon completion of each technology package, the clinical trials will be set up in each region. The clinical trials sizes will be determined by the best available clinical trial data to date, including from recent pharmacotherapy trials, as well as CBT trials, and online therapy trials, including that from the project coordinator. Recruitment will be from both post rehabilitation groups, as well as outpatient alone recruitment for the clinical trial; and from online advertising for the pre-clinical trial.
  Funding Agency

  EU
  Date From

  01-01-2015
  Date To

  30-12-2009
• Title

  The Effect of Naltrexone on Voluntary Alcohol Consumption
  Summary

  Co-investigator, Ran laboratory based self administration of alcohol protocol with 56 patients over 4 years, with significant manuscript writing input. Presented Research Society on Alcoholism (RSA) 1995,
  Funding Agency

  National Institute on Alcoholism and Alcohol Abuse.
  Date From

  12-1-92
  Date To

  11-30-97
• Title

  Research Center: Etiology and Treatment of Alcohol Dependence,
  Summary

  Component Project: Mechanisms of Action: Naltrexone Treatment, Co-investigator, Ran large clinical trial of pharmacotherapy in primary care and psychiatric setting, significant design and manuscript writing input. Presented at College of Problems on Drug Dependence (CPDD) 1995, Published 1997
  Funding Agency

  National Institute on Alcoholism and Alcohol Abuse.
  Date From

  12-1-92
  Date To

  11-30-97.
• Title

  Adminstrative support for application for a clinical trial
  Summary

  Application to Enterprise Ireland for administrative support for an Horizon 2020 application. This grant provided support for travel expenses for other members of the international consortium, support for an administrative company.
  Funding Agency

  EI
  Date From

  01-01-2015
  Date To

  30-12-2016

Mental Health (including Psychiatry and Clinical Psychology),

• RCPsych Academic Researcher of the Year, Finalist 2016
• New Investigator American Society Research Education in Substance Abuse 1-7-1996
• NIH/NIAAA Grant Review Committee 1998-2004
• Psychiatry Award Royal Academy of Medicine in Ireland 1-3-2012

• College of Psychiatrists of Ireland 2021
• American Society for Research and Education in Substance Abuse 2002
• Research Society on Alcoholism 2002
• European Federation of Addiction Societies 2021
• Royal College of Psychiatry 2021
• International Society on Dual Disorders 2021
• International Society for Biomedical Research on Alcoholism 2021

• Presentation to Oireachtas Committee on Arts, Community, Rural and Gaeltacht Affairs 2005
• Editorial Board Member: Alcohol and Alcoholism 2002
• Editorial Board Member: European Addiction Research 2018
• Presentation to Oireachtas Committee on Health 2006
• Editorial Board Member: Irish Journal of Medical Science 2006